Verisante Technology, Inc. Recognizes May as National Skin Cancer Awareness Month
May 02 2014 - 8:00AM
Marketwired
Verisante Technology, Inc. Recognizes May as National Skin Cancer
Awareness Month
VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 2, 2014) -
Verisante Technology, Inc. (TSX-VENTURE:VRS)(OTCQX:VRSEF) (the
"Company" or "Verisante"), a leader in cancer detection technology,
recognizes May as skin cancer awareness month and reminds the
public to wear sunscreen and get screened for skin cancer.
Skin cancer is the most common form of cancer in the world, with
the World Health Organization reporting one in every three cancers
diagnosed is a skin cancer. The incidence of both non-melanoma and
melanoma skin cancers have been increasing at a rate of
approximately 3% per year. One in seven Canadians will develop skin
cancer during their lifetime while one in five Americans will, and
over 3.5 million cases of skin cancer are diagnosed annually in the
USA.
The good news is that early detection through regular skin
cancer screenings and the daily use of sunscreen can be highly
effective in preventing the spread of the disease.
Verisante Aura™, a device for the detection of skin cancer, is
now being used by doctors in Canada to assist them in the
assessment of skin cancer. Skin cancer patients are urged to ask
their doctor about the benefits of an AuraScan™.
"Verisante has placed two additional Aura's™ in Canada in the
past two months," said Thomas Braun, President and CEO. "The
Company's direct sales team, which was established in February,
continues to make excellent progress in assessing additional
locations across the country where Aura™ will be most useful to
doctors and patients."
In honour of Melanoma May, a medical clinic in downtown Toronto
is offering a chance to win one of five non-invasive skin cancer
assessments using Aura™. Patients may enter to win through the
clinic's website.
Medical Professionals interested in learning more about using
Aura™ in their practice can contact the Company directly at
info@verisante.com
About Verisante
Technology, Inc.
Verisante is a medical device company committed to
commercializing innovative systems for the early detection of
cancer. The Verisante Aura™ for skin cancer detection and the
Verisante Core™ series for lung, colon and cervical cancer
detection utilize a proprietary cancer detection platform while the
operating software and probe technology are unique to each device.
The cancer detection platform was developed by the BC Cancer Agency
and tested and refined at the Skin Care Centre at Vancouver General
Hospital. This exclusive platform technology allows Verisante to
develop and offer a range of compact, non-invasive cancer detection
devices that offer physicians immediate results for many of the
most common cancers. Aura™ has been approved for sale in Canada,
Europe and Australia. Core™ has not yet been approved for sale.
Verisante Aura™ was awarded Popular Science Magazine's
"Best of What's New Award" for 2011, awarded a 2013 Prism Award for
Innovation in Photonics and an Edison Award for Excellence in
Innovation in 2013. Verisante Core™ was named one of the top 10
cancer breakthroughs of 2011 by the Canadian Cancer Society.
The TSX Venture Exchange has neither approved nor
disapproved of the contents of this press release. Neither the TSX
Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this press
release.
Forward-Looking Statements
This release contains forward-looking statements, including, but
not limited to, statements regarding the future commercialization
of medical devices, the market demand for these products and the
proprietary protections the Company will obtain with regard to the
technology, all of which statements are subject to market risks,
and the possibility that the Company will not be able to obtain
patent protection or obtain sufficient customer demand. These
statements are made based upon current expectations and actual
results may differ from those projected due to a number of risks
and uncertainties.
Verisante Technology, Inc.Thomas BraunPresident & CEO(604)
605-0507info@verisante.comwww.verisante.comYoutube:
www.youtube.com/verisanteTwitter:
www.twitter.com/verisanteFacebook: www.facebook.com/verisante
Verisante Technology (TSXV:VRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Verisante Technology (TSXV:VRS)
Historical Stock Chart
From Sep 2023 to Sep 2024